Neuraxpharm Slovakia, a. s.
Basic details
- Company ID (IČO)
- 35953021
- Tax ID (DIČ)
- 2022051603
- VAT ID (IČ DPH)
- SK2022051603
- VAT
- Registered for VAT under §4 since 22/9/2005
- Registered office
- Sartorisova 21, 82108 Bratislava
- District
- Bratislava II (SK0102)
- Legal form
- Akciová spoločnosť
- Register entry
- Obchodný register Mestského súdu Bratislava III, oddiel Sa, vložka 3682/B
- Main activity (SK NACE)
- 46.46 · Veľkoobchod s farmaceutickým a zdravotníckym tovarom
- Employees
- 5-9 zamestnancov
- Established
- 3/9/2005
Commercial register
Data updated: 6/11/2026, 07:49 (14 days ago)
- Registered capital
- €33,194 (paid up €33,194)
- Acting for the company
- V mene spoločnosti koná a podpisuje každý člen predstavenstva samostatne. Za spoločnosť podpisuje tak, že k obchodnému menu spoločnosti pripojí podpisujúci svoj podpis. Predstavenstvo môže k podpisu a konaniu menom spoločnosti v stanovenom rozsahu splnomocniť aj tretie osoby.
Shareholders
- Aida Fernandez Ibañezfrom 4/5/2021
- Burghard Burczyk-Adelsbergerfrom 4/5/2021
- Miguel Barrero Duránfrom 30/10/2026
- Neuraxpharm Bohemia s.r.o.from 3/11/2022
Statutory body
- Dr. Maximilian Von Wülfingfrom 23/1/2023
- Francisco Jurado Sanchezfrom 4/5/2021
- Jacek Sawickifrom 19/2/2024
This is a copy from the Register of Legal Entities, not a court extract for legal acts. Look up on orsr.sk
Peppol
We found no entry for its tax ID in the OpenPeppol Directory. Listing in the directory is voluntary, so this does not mean the company does not use Peppol.
Bank accounts

SK27 7500 0000 0040 0268 5451
Accounts the Slovak Financial Administration publishes for VAT payers.
Connections
Neuraxpharm Slovakia, a. s.
FinPOST.sk
Financial data
No selected figures are published for this company or year.
FinPOST.sk
Financial data
From the financial statements in the Register of Financial Statements (RÚZ), in euros, for the last 5 years (each column is one fiscal year). Not verified; shown as the company filed them.
In 2021, Neuraxpharm Slovakia, a. s. decreased its revenue by 14% to €1,215,187 and made a loss of €104,923. Equity was −€262,446 and the debt ratio rose to 159.81%.
In 2022, Neuraxpharm Slovakia, a. s. increased its revenue by 9% to €1,327,907 and made a loss of €129,820. Equity was −€449,540 and the debt ratio rose to 195.67%.
In 2023, Neuraxpharm Slovakia, a. s. decreased its revenue by 0% to €1,324,697 and made a loss of €137,111. Equity was −€586,651 and the debt ratio rose to 252.92%.
In 2024, Neuraxpharm Slovakia, a. s. decreased its revenue by 21% to €1,048,576 and made a loss of €277,447. Equity was −€864,098 and the debt ratio rose to 643.71%.
In 2025, Neuraxpharm Slovakia, a. s. decreased its revenue by 12% to €925,497 and made a loss of €85,177. Equity was −€949,275 and the debt ratio fell to 511.14%.
Revenue
Neuraxpharm Slovakia, a. s.
| Year | Revenue |
|---|---|
| 2021 | €1,215,187 |
| 2022 | €1,327,907 |
| 2023 | €1,324,697 |
| 2024 | €1,048,576 |
| 2025 | €925,497 |
Profit
Neuraxpharm Slovakia, a. s.
| Year | Profit |
|---|---|
| 2021 | −€104,923 |
| 2022 | −€129,820 |
| 2023 | −€137,111 |
| 2024 | −€277,447 |
| 2025 | −€85,177 |
- Revenue
- €1,215,187
- Profit
- −€104,923
- Assets
- €438,832
- Equity and liabilities
- €438,832
- Equity
- −€262,446
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 159.81%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 26.46%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €1,327,907
- Profit
- −€129,820
- Assets
- €469,886
- Equity and liabilities
- €469,886
- Equity
- −€449,540
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 195.67%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 27.77%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €1,324,697
- Profit
- −€137,111
- Assets
- €383,634
- Equity and liabilities
- €383,634
- Equity
- −€586,651
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 252.92%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 31.35%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €1,048,576
- Profit
- −€277,447
- Assets
- €158,927
- Equity and liabilities
- €158,927
- Equity
- −€864,098
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 643.71%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 17.01%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
- Revenue
- €925,497
- Profit
- −€85,177
- Assets
- €230,890
- Equity and liabilities
- €230,890
- Equity
- −€949,275
- Debt ratio What it shows: How much of its assets the company finances with borrowed funds.
How it is computed: (Liabilities + Accruals) / Assets - 511.14%
- Gross margin What it shows: The share of revenue left after the cost of goods, materials, energy and services.
How it is computed: Value added / Revenue - 33.55%
Financial statements as PDF
The files open in the Register of Financial Statements (RÚZ) in a new tab.
Assets
Neuraxpharm Slovakia, a. s.
As of 31/12/2021
- €438,832 · 100.00%
As of 31/12/2022
- €469,886 · 100.00%
As of 31/12/2023
- €383,634 · 100.00%
As of 31/12/2024
- €158,927 · 100.00%
As of 31/12/2025
- €230,890 · 100.00%
Equity and liabilities
Neuraxpharm Slovakia, a. s.
As of 31/12/2021
- €438,832 · 100.00%
As of 31/12/2022
- €469,886 · 100.00%
As of 31/12/2023
- €383,634 · 100.00%
As of 31/12/2024
- €158,927 · 100.00%
As of 31/12/2025
- €230,890 · 100.00%
Total income
Neuraxpharm Slovakia, a. s.
| Year | Sales of goods, products and services | Sales of fixed assets and material | Other operating income | Other financial income | Total |
|---|---|---|---|---|---|
| 2021 | €1,215,187 | €0 | −€685 | €2,952 | €1,217,454 |
| 2022 | €1,327,907 | €150 | €102 | €953 | €1,329,112 |
| 2023 | €1,324,697 | €232 | €20 | €22,355 | €1,347,304 |
| 2024 | €1,048,576 | €1,335 | €0 | €13,650 | €1,063,561 |
| 2025 | €925,497 | €270 | €0 | €132 | €925,899 |
Costs
Neuraxpharm Slovakia, a. s.
| Year | Cost of goods sold | Materials and energy | Services | Personnel costs | Depreciation | Other operating costs | Financial costs | Income tax | Total |
|---|---|---|---|---|---|---|---|---|---|
| 2021 | €360,001 | €73,217 | €460,433 | €351,991 | €906 | €46,407 | €29,422 | €0 | €1,322,377 |
| 2022 | €299,933 | €80,505 | €578,698 | €416,082 | €1,504 | €61,655 | €20,555 | €0 | €1,458,932 |
| 2023 | €294,946 | €16,239 | €598,255 | €529,852 | €3,403 | €34,428 | €7,292 | €0 | €1,484,415 |
| 2024 | €151,039 | €42,374 | €676,757 | €449,751 | €3,085 | €11,982 | €2,180 | €3,840 | €1,341,008 |
| 2025 | €103,240 | €26,964 | €484,766 | €350,966 | €4,564 | €10,833 | €25,903 | €3,840 | €1,011,076 |
Margins
Neuraxpharm Slovakia, a. s.
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2021 | 26.46% | −6.46% | −8.63% |
| 2022 | 27.77% | −8.30% | −9.78% |
| 2023 | 31.35% | −11.49% | −10.35% |
| 2024 | 17.01% | −27.19% | −26.46% |
| 2025 | 33.55% | −6.00% | −9.20% |
Year-on-year change
Neuraxpharm Slovakia, a. s.
| Year | Revenue | Profit |
|---|---|---|
| 2021 | −14% | – |
| 2022 | 9% | – |
| 2023 | 0% | – |
| 2024 | −21% | – |
| 2025 | −12% | – |
Financing structure
Neuraxpharm Slovakia, a. s.
| Year | Equity | Provisions | Long-term liabilities | Short-term liabilities | Accruals |
|---|---|---|---|---|---|
| 2021 | −€262,446 | €18,267 | €4,603 | €634,744 | €43,664 |
| 2022 | −€449,540 | €20,535 | €4,115 | €870,021 | €24,755 |
| 2023 | −€586,651 | €15,672 | €2,848 | €820,437 | €131,328 |
| 2024 | −€864,098 | €10,930 | €2,373 | €754,733 | €254,989 |
| 2025 | −€949,275 | €12,102 | €1,945 | €938,426 | €227,692 |
Income tax
Neuraxpharm Slovakia, a. s.
| Year | Income tax | Current tax |
|---|---|---|
| 2021 | €0 | €0 |
| 2022 | €0 | €0 |
| 2023 | €0 | €0 |
| 2024 | €3,840 | €3,840 |
| 2025 | €3,840 | €3,840 |
Data sources
- Financial Administration of the Slovak Republic · updated 20/11/2026
- Register of Legal Entities (Statistical Office of the Slovak Republic, licence CC BY 4.0) · updated 20/11/2026
- OpenPeppol Directory · updated 20/11/2026
- Register of Financial Statements (RÚZ) · updated 20/11/2026
We take the data from the public registers as they publish it, unchanged and untranslated. FinPOST is an information website and does not verify the data. This page may be up to 7 days old. How we handle the data (privacy policy, section 3.9)